MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Create the #1 medical social network (Video/Pictures)
Global aggregator of choice for advanced medical technology business intelligence
Innovation & Royalty Aggregator
Royalty Pharma plc (NASDAQ:RPRX)
Finance & Acquisitions: Royalty Pharma
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR)*
Organization & Developments: Arrowhead
Parents
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR)*
Children
*Arrowhead, has a drug delivery platform called TRiM. TRiM stands for targeted RNAi Molecule platform
*DEVELOPS RNAI INTERFERENCE AND PEPTIDE DRUG CONJUGATES FOR A WIDE RANGE OF DISEASES.
2015: Arrowhead Hits Target In Hepatitis B Drug Trial ARWR ABUS ALNY GILD
2016: Arrowhead Pharmaceuticals' Clinical Hold Woes Are Overblown - Arrowhead Pharmaceuticals (NASDAQ:ARWR)
2016: Downgrades hit Arrowhead after price plunge - Arrowhead Pharmaceuticals (NASDAQ:ARWR)
2018: Arrowhead Pharmaceuticals Could Become The Next Gilead_seekingalpha.com
2018: Arrowhead's Data Proves That It Can Be A Big Contender In The Hepatitis B Space_ seekingalpha.com
2018: Johnson & Johnson pays $175M, commits to $1.6B in milestones for Arrowhead hepatitis B drug
2019: Arrowhead Pharmaceuticals: Looks To Be Time For Another Breakout_seekingalpha.com
2019: This Biotech Stock With A 221% Gain In 2019 Is Ready For 'Prime Time'_www.investors.com
2020: Arrowhead Is A Buy On Takeda Deal And Massive Pipeline
2020: Arrowhead Pharmaceuticals Is A Smart Long-Term Opportunity
2020: How Arrowhead Protects Its Intellectual Property
2021: Arrowhead: Steady Progress With Lead Indication, Vast Pipeline
2022: Arrowhead Pharmaceuticals (ARWR) Presents at AHA Scientific Sessions 2022_ seekingalpha.com
2022: Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities_seekingalpha.com
2022: Arrowhead Pharmaceuticals: Olpasiran's Impressive Phase 2 Data_ seekingalpha.com
2022: Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency_New England Journal of Medicine
2023: Arrowhead Pharmaceuticals Remains A Buy For Pipeline Potential (NASDAQ:ARWR)
2023: Arrowhead stock dips ~15% amid phase 2 data for liver disease drug fazirsiran_ seekingalpha.com
2024: Arrowhead Pharma Lands $825M Mega-Deal with Sarepta, Up to $10B inMilestones
2024: Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Program
2024: Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy_seekingalpha.com
2024: Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)
2024: Arrowhead: The Sarepta Partnership Validates RNAi Platform And Reduces Risk
2024: Sarepta pays $500M cash for rights to 'multiple potential blockbusters' from Arrowhead
2024: Sarepta rebuilds drug pipeline with Arrowhead deal
2025 Arrowhead Pharmaceuticals: A Reluctant Sell Rating Explained (Rating Downgrade)
2025: Arrowhead Pharmaceuticals Is Finally Arriving
2025: Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions
2025: Novartis bets $200M upfront on Arrowhead’s Parkinson’s RNAi, total value up to $2.2B
Jumps
*Key People: Arrowhead
Finance & Acquisitions: Arrowhead